Form 4: Lyra CFO Sells Shares for Tax Obligations

Lyra Therapeutics' Chief Financial Officer, Jason Cavalier, sold 769 shares of common stock on January 6, 2026, to cover tax liabilities from RSU vesting.

Summary

• Jason Cavalier, Chief Financial Officer of Lyra Therapeutics, Inc., reported a sale of common stock.
• The transaction involved the disposition of 769 shares of Lyra Therapeutics common stock.
• The shares were sold on January 6, 2026, at a price of $3.364 per share.
• The sale was executed to cover tax obligations arising from the vesting of restricted stock units (RSUs).
• This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, which was adopted by Mr. Cavalier on January 1, 2025.
• Following this transaction, Mr. Cavalier beneficially owns 518,547 shares of common stock.

Sentiment

Score: 5

Explanation: Neutral. This is a routine, pre-planned transaction by an insider to cover tax obligations upon RSU vesting, which is a common occurrence and does not reflect a change in sentiment towards the company's prospects.

Positives

• The transaction was pre-planned under a Rule 10b5-1 plan, indicating a structured approach to managing equity compensation and reducing concerns about opportunistic trading.

Negatives

• A sale of shares by a key executive, even for tax purposes, reduces their direct ownership stake in the company.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Minor dilution from the sale, but the transaction is routine and pre-planned, so unlikely to cause significant concern.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 reports a routine, pre-planned sale of shares by a CFO to cover tax obligations upon RSU vesting. Such transactions are common and do not typically indicate a change in the executive's confidence in the company or signal any fundamental shift in the company's prospects. Therefore, it provides no new information that would warrant a change in an investor's existing position.

Keywords

Lyra Therapeutics, LYRA, Jason Cavalier, CFO, Insider Trading, Form 4, Stock Sale, RSU Vesting, Tax Obligations, 10b5-1 Plan